Search for: "Pharmacia " Results 1 - 20 of 179
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
On August 4, 2022, the New Jersey Department of Environmental Protection (NJDEP) issued a press release announcing a lawsuit of sweeping, breathtaking scope against Monsanto, Solutia, and Pharmacia ─ all linked to the original Monsanto (“Old Monsanto”), which reorganized its businesses into three separate corporations in the late 1990s ─ seeking natural resource damages (NRDs) for polychlorinated biphenyl (PCB) contamination across the entire state of New Jersey. [read post]
On August 4, 2022, the New Jersey Department of Environmental Protection (NJDEP) issued a press release announcing a lawsuit of sweeping, breathtaking scope against Monsanto, Solutia, and Pharmacia ─ all linked to the original Monsanto (“Old Monsanto”), which reorganized its businesses into three separate corporations in the late 1990s ─ seeking natural resource damages (NRDs) for polychlorinated biphenyl (PCB) contamination across the entire state of New Jersey. [read post]
On August 4, 2022, the New Jersey Department of Environmental Protection (NJDEP) issued a press release announcing a lawsuit of sweeping, breathtaking scope against Monsanto, Solutia, and Pharmacia ─ all linked to the original Monsanto (“Old Monsanto”), which reorganized its businesses into three separate corporations in the late 1990s ─ seeking natural resource damages (NRDs) for polychlorinated biphenyl (PCB) contamination across the entire state of New Jersey. [read post]
Sugen LLC and Pharmacia & Upjohn Company In February 2019, the Moscow City Commercial Court granted a second compulsory license to Nativa for use of a drug named Sunitinib was protected by an Eurasian patent co-owned by Sugen LLC and Pharmacia & Upjohn Company, both of which were owned by Pfizer. [read post]
8 Sep 2020, 2:59 pm by Kevin LaCroix
As the Court in the insurance coverage litigation later summarized, the Garber Action alleged that Pfizer, as successor in interest to Pharmacia, had misled investors about the adverse gastrointestinal effects of Celebrex, an anti-inflammatory drug. [read post]
While the CJEU had initially endorsed a restrictive approach in Pharmacia Italia (C-31/03), MIT (C-431/04) and Yissum (C-202/05), it surprisingly made a complete U-turn in the Neurim judgment (C-130/11) rendered in 2012. [read post]
While the CJEU had initially endorsed a restrictive approach in Pharmacia Italia (C-31/03), MIT (C-431/04) and Yissum (C-202/05), it surprisingly made a complete U-turn in the Neurim judgment (C-130/11) rendered in 2012. [read post]
23 Jan 2020, 12:55 pm by Alexa von Uexküll
The Neurim decision is highly controversial, as it is in conflict with the literal wording of the provisions of the SPC Regulation, as well as the previous standing case law, as evidenced by Pharmacia (C-31/03), Yissum (C-202/05) and MIT (C-431/04). [read post]
20 Dec 2019, 9:08 am by Holly Buckley
Humana will also acquire Enclara Pharmacia, GuidantRx, and Avanti Health Care Services from Consonance as part of the transaction, reports HealthLeaders. [read post]
20 Dec 2019, 9:08 am by Holly Buckley
Humana will also acquire Enclara Pharmacia, GuidantRx, and Avanti Health Care Services from Consonance as part of the transaction, reports HealthLeaders. [read post]
7 Aug 2019, 1:42 am
The IPCom guidance are provided for readers' convenience at the end of this post.The IPCom factors have since been applied in Actavis v Pharmacia [2014] EWHC 2265 (stay was ordered), and Eli Lilly v Janssen Sciences [2016] EWHC 313 (stay was not ordered) (IPKat post here).David Stone (sitting as a Deputy High Court Judge), applied the IPCom guidance to the fact of the case in Coloplast v Salts. [read post]
21 Mar 2019, 10:16 am
  Abraxis said they were, as there was an important therapeutic differences between the two and thus subject to two different MAs, the latter being the "first MA" (thus complying with Article 3(d)).Mr Justice Arnold considered there was inconsistency in the CJEU judgments as between Neurim and Pharmacia or Yissum. [read post]
23 Dec 2018, 4:01 am
The AG refers to CJEU case-law in Yissum and Pharmacia Italia, providing that the definition of the term “product” is independent of the therapeutic use concerned, meaning that an active ingredient or a “combination of active ingredients” remains the same product irrespective of the different therapeutic uses this might have. [read post]
5 Sep 2017, 2:50 pm by Matt Pulle
Pharmacia & Upjohn Absence Payment Plan, (2006), the Sixth Circuit re-iterated that while “some weight is to be given” to an SSA determination of total disability, “it is not binding. [read post]
25 Jan 2017, 11:25 pm
He notes that the Neurim decision seems to be inconsistent with the CJEU’s decisions in MIT, GSK, Pharmacia and Yissum. [read post]
16 Jan 2017, 6:45 am by Brian Cordery
It is interesting to note that, on reviewing the authorities, Arnold J once again expressed concern regarding the compatibility of Neurim on the one hand and Pharmacia (C-31/03) and Yissum (C-202/05) on the other. [read post]
2 Nov 2016, 4:57 am by Amber Walsh
The healthcare and life sciences sectors have grown at a rapid pace during recent years. [read post]